Toll样受体激动剂及其在肿瘤疫苗中的应用研究进展

doi:10.11958/20253005

天津医药 ›› 2026, Vol. 54 ›› Issue (5): 550-555.doi: 10.11958/20253005

Toll样受体激动剂及其在肿瘤疫苗中的应用研究进展

徐彤¹(), 杨星旺², 刘永辉^2△()

¹ 天津中医药大学第一附属医院，国家中医针灸临床医学研究中心（邮编 300073）
² 天津工业大学化学学院

收稿日期:2025-09-23 修回日期:2025-12-31 出版日期:2026-05-15 发布日期:2026-05-13
通讯作者: ^△E-mail：liuyonghui@tiangong.edu.cn
作者简介:徐彤（1990），女，主管药师，主要从事疫苗佐剂和递送载体方面研究。E-mail：xu_tjtcm@163.com
基金资助:
国家自然科学基金资助项目(82103984)

Research progress on Toll-like receptor agonists and their application in tumor vaccines

XU Tong¹(), YANG Xingwang², LIU Yonghui^2△()

¹ First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300073, China
² School of Chemistry, Tiangong University

Received:2025-09-23 Revised:2025-12-31 Published:2026-05-15 Online:2026-05-13
Contact: ^△E-mail：liuyonghui@tiangong.edu.cn

徐彤, 杨星旺, 刘永辉. Toll样受体激动剂及其在肿瘤疫苗中的应用研究进展[J]. 天津医药, 2026, 54(5): 550-555.

XU Tong, YANG Xingwang, LIU Yonghui. Research progress on Toll-like receptor agonists and their application in tumor vaccines[J]. Tianjin Medical Journal, 2026, 54(5): 550-555.

摘要/Abstract

摘要：

Toll样受体（TLR）激动剂作为肿瘤疫苗佐剂，可有效激活先天免疫并增强抗肿瘤免疫应答。其通过特异性识别病原相关分子模式，激活下游信号通路，促进树突状细胞成熟与抗原提呈，进而诱导强烈的细胞免疫。各类TLR激动剂在肿瘤疫苗中展现出增强免疫原性、逆转免疫抑制及与免疫检查点抑制剂协同的潜力。该文综述了TLR激动剂的分类、作用机制及其在肿瘤疫苗中的研究进展，以期为肿瘤免疫治疗提供参考。

关键词: Toll样受体, 肿瘤疫苗, 激动剂, 佐剂, 抗肿瘤

Abstract:

Toll-like receptor (TLR) agonists, when used as adjuvants in tumor vaccines, can effectively activate the innate immune response and enhance antitumor immune responses. By specifically recognizing pathogen-associated molecular patterns, they activate downstream signaling pathways, promote the maturation and antigen presentation of dendritic cells, and thereby induce strong cellular immunity. Various TLR agonists have shown potential in tumor vaccines to enhance immunogenicity, reverse immune suppression and synergize with immune checkpoint inhibitors. This article reviews the classification, mechanism of action and research progress of TLR agonists in tumor vaccines, aiming to provide a reference for tumor immunotherapy.

Key words: Toll-like receptors, tumor vaccines, agonists, adjuvants, antitumor

中图分类号:

R979.5，R730.5

参考文献 47

[1]	BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. doi:10.3322/caac.21834.
[2]	KAWAI T, IKEGAWA M, ORI D, et al. Decoding Toll-like receptors:recent insights and perspectives in innate immunity[J]. Immunity, 2024, 57(4):649-673. doi:10.1016/j.immuni.2024.03.004.
[3]	FARAG N S, BREITINGER U, BREITINGER H G, et al. Viroporins and inflammasomes:a key to understand virus-induced inflammation[J]. Int J Biochem Cell Biol, 2020, 122:105738. doi:10.1016/j.biocel.2020.105738.
[4]	FITZGERALD K A, KAGAN J C. Toll-like receptors and the control of immunity[J]. Cell, 2020, 180(6):1044-1066. doi:10.1016/j.cell.2020.02.041.
[5]	PEREIRA M, GAZZINELLI R T. Regulation of innate immune signaling by IRAK proteins[J]. Front Immunol, 2023, 14:1133354. doi:10.3389/fimmu.2023.1133354.
[6]	CHEN Y H, WU K H, WU H P. Unraveling the complexities of Toll-like receptors:from molecular mechanisms to clinical applications[J]. Int J Mol Sci, 2024, 25(9):5037. doi:10.3390/ijms25095037.
[7]	JIN M, FANG J, WANG J J, et al. Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis:from mechanisms to targeted therapeutics[J]. Acta Pharmacol Sin, 2023, 44(12):2358-2375. doi:10.1038/s41401-023-01123-5.
[8]	ZHAO H, WU L, YAN G, et al. Inflammation and tumor progression:signaling pathways and targeted intervention[J]. Signal Transduct Target Ther, 2021, 6(1):263. doi:10.1038/s41392-021-00658-5.
[9]	MENG T, GAO T, QIAO F, et al. A VZV-gE subunit vaccine decorated with PLA elicits protective cellular immune responses against varicella-zoster virus[J]. Int Immunopharmacol, 2025, 147:114033. doi:10.1016/j.intimp.2025.114033.
[10]	JIANG Y, ZHANG H, WANG J, et al. Exploiting RIG-I-like receptor pathway for cancer immunotherapy[J]. J Hematol Oncol, 2023, 16(1):8. doi:10.1186/s13045-023-01405-9.
[11]	CHAMPION C R. Heplisav-B:A hepatitis B vaccine with a novel adjuvant[J]. Ann Pharmacother, 2021, 55(6):783-791. doi:10.1177/1060028020962050.
[12]	CHAKRABORTY S, YE J, WANG H, et al. Application of toll-like receptors(TLRs)and their agonists in cancer vaccines and immunotherapy[J]. Front Immunol, 2023, 14:1227833. doi:10.3389/fimmu.2023.1227833.
[13]	UMAR M, AFZAL H, MURTAZA A, et al. Lipoprotein signal peptide as adjuvants:leveraging lipobox-driven TLR2 activation in modern vaccine design[J]. Vaccines (Basel), 2025, 13(1):36. doi:10.3390/vaccines13010036.
[14]	XIE D, HAN C, CHEN C, et al. A scaffold vaccine to promote tumor antigen cross-presentation via sustained toll-like receptor-2 (TLR2) activation[J]. Bioact Mater, 2024, 37:315-330. doi:10.1016/j.bioactmat.2024.03.035.
[15]	GU Y, YANG J, HE C, et al. Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases[J]. Signal Transduct Target Ther, 2023, 8(1):273. doi:10.1038/s41392-023-01479-4.
[16]	KOMAL A, NOREEN M, EL-KOTT A F. TLR3 agonists:RGC100,ARNAX,and poly-IC:a comparative review[J]. Immunol Res, 2021, 69(4):312-322. doi:10.1007/s12026-021-09203-6.
[17]	HSIEH M L, NISHIZAKI D, ADASHEK J J, et al. Toll-like receptor 3:a double-edged sword[J]. Biomark Res, 2025, 13(1):32. doi:10.1186/s40364-025-00739-5.
[18]	WENG M T, YANG S F, LIU S Y, et al. In situ vaccination followed by intramuscular poly-ICLC injections for the treatment of hepatocellular carcinoma in mouse models[J]. Pharmacol Res, 2023, 188:106646. doi:10.1016/j.phrs.2023.106646.
[19]	KOERNER J, HORVATH D, HERRMANN V L, et al. PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy[J]. Nat Commun, 2021, 12(1):2935. doi:10.1038/s41467-021-23244-3.
[20]	李如月, 向晓辉, 张斌, 等. TLR4信号通路相关miRNAs在炎症反应调节中的研究进展[J]. 天津医药, 2017, 45(7):771-776.
	LI R Y, XIANG X H, ZHANG B, et al. Research progress of TLR4 signaling pathway related miRNAs in inflammatory response[J]. Tianjin Med J, 2017, 45(7):771-776. doi:10.11958/20170207.
[21]	DING D, WEN Y, LIAO C M, et al. Self-adjuvanting protein vaccine conjugated with a novel synthetic TLR4 agonist on virus-like liposome induces potent immunity against SARS-CoV-2[J]. J Med Chem, 2023, 66(2):1467-1483. doi:10.1021/acs.jmedchem.2c01642.
[22]	SEO B, LIM M Y. Balancing harm and harmony:evolutionary dynamics between gut microbiota-derived flagellin and TLR5-mediated host immunity and metabolism[J]. Virulence, 2025, 16(1):2512035. doi:10.1080/21505594.2025.2512035.
[23]	TALUKDER A, RAHMAN M M, RAHI M S, et al. Flagellins as vaccine adjuvants and cancer immunotherapy:recent advances and future prospects[J]. Immunology, 2025, 176(3):277-303. doi:10.1111/imm.70001.
[24]	EULIANO E M, POGOSTIN B H, AGRAWAL A, et al. A TLR7 agonist conjugated to a nanofibrous peptide hydrogel as a potent vaccine adjuvant[J]. Adv Healthc Mater, 2026, 14(3):e2402958. doi:10.1002/adhm.202402958.
[25]	SUN H, LI Y, ZHANG P, et al. Targeting toll-like receptor 7/8 for immunotherapy:recent advances and prospectives[J]. Biomark Res, 2022, 10(1):89. doi:10.1186/s40364-022-00436-7.
[26]	LUO L, WANG X, LIAO Y P, et al. Nanocarrier co-formulation for delivery of a TLR7 agonist plus an immunogenic cell death stimulus triggers effective pancreatic cancer chemo-immunotherapy[J]. ACS Nano, 2022, 16(8):13168-13182. doi:10.1021/acsnano.2c06300.
[27]	GANE E J, DUNBAR P R, BROOKS A E, et al. Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression[J]. J Hepatol, 2023, 78(3):513-523. doi:10.1016/j.jhep.2022.09.027.
[28]	KAUR A, BALDWIN J, BRAR D, et al. Toll-like receptor(TLR)agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics[J]. Curr Opin Chem Biol, 2022, 70:102172. doi:10.1016/j.cbpa.2022.102172.
[29]	XU R, WU M, LIU S, et al. Glucose metabolism characteristics and TLR8-mediated metabolic control of CD4+ Treg cells in ovarian cancer cells microenvironment[J]. Cell Death Dis, 2021, 12(1):22. doi:10.1038/s41419-020-03272-5.
[30]	王丹妮, 郑贵杰, 张翼, 等. Toll样受体激动剂及其作为寄生虫疫苗佐剂研究进展[J]. 中国人兽共患病学报, 2024, 40(11):1063-1072.
	WANG D N, ZHENG G J, ZHANG J, et al. Research progress in Toll-like receptor agonist types and applications as adjuvants for parasitics vaccine[J]. Chinese Journal of Zoonoses, 2024, 40(11):1063-1072. doi:10.3969/j.issn.1002-2694.2024.00.158.
[31]	CHENG Y, BORCHERDING N, OGUNSAKIN A, et al. The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent[J]. Sci Rep, 2021, 11(1):1535. doi:10.1038/s41598-020-80957-z.
[32]	MACKMAN R L, MISH M, CHIN G, et al. Discovery of GS-9688 (selgantolimod) as a potent and selective oral Toll-like receptor 8 agonist for the treatment of chronic hepatitis B[J]. J Med Chem, 2020, 63(18):10188-10203. doi:10.1021/acs.jmedchem.0c00100.
[33]	FEHRI E, ENNAIFER E, BEL HAJ RHOUMA R, et al. TLR9 and glioma:friends or foes?[J]. Cells, 2022, 12(1):152. doi:10.3390/cells12010152.
[34]	KOU M, WANG L. Surface toll-like receptor 9 on immune cells and its immunomodulatory effect[J]. Front Immunol, 2023, 14:1259989. doi:10.3389/fimmu.2023.1259989.
[35]	XING J, ZHAO X, LI X, et al. The recent advances in vaccine adjuvants[J]. Front Immunol, 2025, 16:1557415. doi:10.3389/fimmu.2025.1557415.
[36]	LIU M, LIU L, SONG Y, et al. Targeting macrophages:a novel treatment strategy in solid tumors[J]. J Transl Med, 2022, 20(1):586. doi:10.1186/s12967-022-03813-w.
[37]	GUNST J D, HØJEN J F, PAHUS M H, et al. Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence:the randomized phase 2a TITAN trial[J]. Nat Med, 2023, 29(10):2547-2558. doi:10.1038/s41591-023-02547-6.
[38]	LEMKE-MILTNER C D, BLACKWELL S E, YIN C, et al. Antibody opsonization of a TLR9 agonist-containing virus-like particle enhances in situ immunization[J]. J Immunol, 2020, 204(5):1386-1394. doi:10.4049/jimmunol.1900742.
[39]	SULTAN H, SALAZAR A M, CELIS E. Poly-ICLC,a multi-functional immune modulator for treating cancer[J]. Semin Immunol, 2020, 49:101414. doi:10.1016/j.smim.2020.101414.
[40]	HUANG L, RONG Y, TANG X, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer[J]. Mol Cancer, 2022, 21(1):45. doi:10.1186/s12943-022-01515-x.
[41]	LI R, HAO Y, PAN W, et al. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy[J]. Acta Biomater, 2023, 171:482-494. doi:10.1016/j.actbio.2023.09.013.
[42]	ZHANG L, WU S, QIN Y, et al. Targeted codelivery of an antigen and dual agonists by hybrid nanoparticles for enhanced cancer immunotherapy[J]. Nano Lett, 2019, 19(7):4237-4249. doi:10.1021/acs.nanolett.9b00030.
[43]	BALJON J J, KWIATKOWSKI A J, PAGENDARM H M, et al. A cancer nanovaccine for co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists[J]. ACS Nano, 2024, 18(9):6845-6862. doi:10.1021/acsnano.3c04471.
[44]	LEŚNIAK M, LIPNIARSKA J, MAJKA P, et al. The role of TRL7/8 agonists in cancer therapy,with special emphasis on hematologic malignancies[J]. Vaccines (Basel), 2023, 11(2):277. doi:10.3390/vaccines11020277.
[45]	陈敏纯, 薛润青, 赵新, 等. 肿瘤疫苗TCL/CpG@GNP的构建及评价[J]. 天津医药, 2025, 53(10):1021-1026.
	CHEN M C, XUE R Q, ZHAO X, et al. Development and evaluation of the tumor vaccine TCL/CpG@GNP[J]. Tianjin Med J, 2025, 53(10):1021-1026. doi:10.11958/20251525.
[46]	LI F, DING X, LV Z, et al. A DNA-polymer hybrid nanocomplex based bi-adjuvant vaccine for tumor immunotherapy[J]. Nano Today, 2024, 54:102061. doi:10.1016/j.nantod.2023.102061.
[47]	NI Q, ZHANG F, LIU Y, et al. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer[J]. Sci Adv, 2020, 6(12):eaaw6071. doi:10.1126/sciadv.aaw6071.

Toll样受体激动剂及其在肿瘤疫苗中的应用研究进展

Research progress on Toll-like receptor agonists and their application in tumor vaccines

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 47

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘家妮, 苏帅, 张爱婷, 徐昕, 王邦茂. 霍乱毒素抗肿瘤作用的研究进展[J]. 天津医药, 2026, 54(4): 438-443.
[2]	姜天佑, 李敏, 孙碧文, 李越洋, 邢丽静, 田晨. Let-7b诱导白血病相关巨噬细胞复极抑制AML的发展[J]. 天津医药, 2026, 54(3): 225-231.
[3]	冯昊, 郭晓双, 任晓静, 李明. 吴茱萸汤联合甲磺酸多拉司琼治疗化疗所致呕吐的疗效分析[J]. 天津医药, 2026, 54(2): 201-205.
[4]	黄慧琦, 伍秋苑, 张昆, 李佩贤, 熊亚明, 叶国麟, 周丹. 川楝素联合奥拉帕尼在三阴性乳腺癌中的抗肿瘤机制研究[J]. 天津医药, 2025, 53(9): 897-902.
[5]	吴素勤, 徐子舒, 许智晶, 吴洁, 王聪梅. 重症颅脑损伤减压术患者血清MMP-10、TLR2水平及其与疾病转归的关系[J]. 天津医药, 2025, 53(7): 704-708.
[6]	陈敏纯, 薛润青, 赵新, 张萌, 叶丹, 张婧一, 郑洁. 肿瘤疫苗TCL/CpG@GNP的构建及评价[J]. 天津医药, 2025, 53(10): 1021-1026.
[7]	徐彤, 张微, 刘永辉. 树突状细胞外泌体作为疫苗载体的研究进展[J]. 天津医药, 2025, 53(10): 1115-1120.
[8]	范慧慧, 任玉梅, 田新磊, 张凯, 李晓丽. 止咳平喘方对支气管哮喘小鼠气道炎症及TLR4/TRAF6/NF-κB通路的影响[J]. 天津医药, 2024, 52(9): 924-929.
[9]	贾维宁, 鲍亚玲, 雷慧, 殷晓宁. 夏枯草提取物对脓毒症小鼠炎症反应和腹腔巨噬细胞的影响[J]. 天津医药, 2024, 52(9): 930-935.
[10]	秦汉林, 胡长路, 赵亚梅, 牛维纳. 四联方案预防含顺铂方案多日化疗致恶心呕吐的效果和安全性研究[J]. 天津医药, 2024, 52(8): 835-839.
[11]	叶朝阳, 马建中, 李后俊, 魏鲲鹏. 急性胰腺炎患者外周血TLR4、IL-1β、NLR水平与疾病进展和预后的关系[J]. 天津医药, 2024, 52(6): 648-652.
[12]	林瑶, 刘从娜, 王世霞, 张志勇. 金合欢素调节HMGB1/TLR4信号通路对脂多糖诱导牙髓细胞凋亡的影响[J]. 天津医药, 2024, 52(12): 1238-1243.
[13]	龙华, 陈怡霏, 王庆书. 瑞马唑仑调节TLR4/MyD88/NF-κB信号通路对烧伤大鼠肠上皮细胞凋亡的影响[J]. 天津医药, 2024, 52(11): 1152-1157.
[14]	张志强, 王威威, 董腾靖, 连鸿凯. 强直性脊柱炎患者外周血TLR4、JAK3基因表达与Th17/Treg失衡的关系[J]. 天津医药, 2024, 52(10): 1065-1068.
[15]	姜忠敏, 张春艳, 刘敏, 郑洁, 李艳霞, 仁青措, 孟纬, 刘晓智. 微乳头型肺腺癌类器官的构建及其靶向药物的筛选[J]. 天津医药, 2024, 52(1): 22-27.